What question did this study set out to answer?

To determine the maximum-tolerated dose (MTD) and characterize the pharmacologic behavior of topotecan as a novel treatment for advanced solid malignancies.

April 1, 1992Journal of Clinical Oncology

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

View Full Paper

Ask AI

Bookmark

To determine the maximum-tolerated dose (MTD) and characterize the pharmacologic behavior of topotecan as a novel treatment for advanced solid malignancies.
Administered topotecan by 30-minute infusions daily for 5 days every 3 weeks to 30 patients with advanced solid tumors
Doses ranged from 0.5 to 2.5 mg/m2/d to assess safety and pharmacologic effects
Monitored for adverse effects like neutropenia and responses in specific carcinomas.
1.5 and 2.0 mg/m2 doses led to grade 3 and 4 neutropenia in most patients, which was brief and rarely caused treatment delays
At 2.5 mg/m2, severe neutropenia occurred, frequently with fever and treatment delays
Responses to treatment noted in non-small-cell lung carcinoma and platinum-refractory ovarian carcinoma.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase I trial evaluates topotecan's effects, showing dose-limiting neutropenia in cancer patients, indicating clinical potential.

Cite This Study

Rowinsky et al. (1992) studied this question.

synapsesocial.com/papers/6a082ba61e0fcf4a43e8adde https://doi.org/10.1200/jco.1992.10.4.647

View Full Paper

Ask AI

Bookmark

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

Key Points

Discussion

Implication

Cite This Study

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider